Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | CCR4 | P51679 | 6/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BID | P55957 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.40 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13510442 | 0.86 | BRAF (0.62) | BRAFHSD11B1EP300MCL1KEAP1 | |
| SCHEMBL13509762 | 0.83 | BRAF (0.60) | BRAFMCL1KEAP1NFE2L2BCL2 | |
| SCHEMBL13509884 | 0.81 | STAT3 (0.55) | BRAFCCR4MCL1KEAP1NFE2L2 | |
| SCHEMBL13510447 | 0.80 | BRAF (0.66) | BRAFHSD11B1EP300MCL1KEAP1 | |
| SCHEMBL13510431 | 0.80 | BRAF (0.69) | BRAFHSD11B1EP300CCR4ALDH1A1 | |
| SCHEMBL13510247 | 0.78 | BRAF (0.44) | BRAFMCL1KEAP1NFE2L2BCL2 | |
| SCHEMBL13510344 | 0.78 | MCL1 (0.47) | BRAFMCL1KEAP1NFE2L2BCL2 | |
| SCHEMBL13510093 | 0.76 | MEN1 (0.63) | BRAFEP300MCL1KEAP1NFE2L2 | |
| SCHEMBL2240501 | 0.73 | BRAF (1.00) | BRAFHSD11B1EP300MCL1KEAP1 | |
| SCHEMBL13578713 | 0.72 | BRAF (0.43) | BRAFHSD11B1EP300CCR4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021113551-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | BAYLOR COLLEGE OF MEDICINE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2020-10-22 | — | — | US | disclosed |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2020-06-09 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE | 2015-01-29 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | STAT3, MMP1, MMP8 | BRAF 1327/4885HSD11B1 2096/4885EP300 35/4885 |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | BRAF 2814/4885HSD11B1 2340/4885EP300 158/4885 |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | BRAF 2814/4885HSD11B1 2340/4885EP300 158/4885 |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | BRAF 2814/4885HSD11B1 2340/4885EP300 158/4885 |
| US-20100041685-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | BRAF 650/4885HSD11B1 3658/4885EP300 223/4885 |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | BRAF 2814/4885HSD11B1 2340/4885EP300 158/4885 |
| US-20140296270-A1 | STAT3 Inhibitors | STAT3, STAT1, JAK2 | BRAF 650/4885HSD11B1 3658/4885EP300 223/4885 |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | JAK2, STAT3, STAT6 | BRAF 1379/4885HSD11B1 1764/4885EP300 95/4885 |
| US-20110312984-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | BRAF 650/4885HSD11B1 3658/4885EP300 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.